DV
Dividend Vision

MAZE — Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE)

Total return is 69.9% over the past 1.5 years, 39.4 points ahead of SPY at 30.5%. Its deepest 1-year drawdown was 54.5%.

MAZE is a single-stock equity fund that tracks Maze Therapeutics, Inc., a company focused on therapeutic development. As a stock fund rather than a diversified ETF, it carries concentrated company risk and currently does not distribute dividends. This fund structure appeals primarily to investors seeking direct exposure to Maze Therapeutics' stock performance rather than those pursuing dividend income or broad market diversification.

MAZE key facts

Asset type
Stock
Asset class
Equity
Inception date
01/30/2025
Distribution frequency
None
Last close
$27.18
Market cap
$1,509,826,432
Average volume
230652.0
Payout ratio
0.0
Forward P/E
8.5324
EPS
$-2.44